Adaptive Biotechnologies

Adaptive Biotechnologies is a life sciences company founded in 2009 that translates the genetic language of the adaptive immune system into products intended to diagnose and treat disease. Its work spans three application areas: life sciences research, clinical diagnostics and drug discovery, with particular focus on hematology and oncology.

The company's clinical offering, clonoSEQ, is a test that helps doctors detect minimal residual disease (MRD) in blood cancer patients with remarkable precision. Alongside it sits the Immune Medicine Platform, a proprietary system developed over more than a decade that decodes immune signals at scale, applying computational biology and machine learning to turn large biological systems into actionable data.

Technical work at the company covers computational biology, machine learning, immune repertoire sequencing, genomics and immunology. The firm is founder-led, having been started by brothers, and describes its purpose as harnessing the immune system's natural power to help people, with a long-term research and development orientation built around its proprietary platform.